Your browser is out of date

With an updated browser, you will have a better Medtronic website experience. Update my browser now.

×

Skip to main content
Play Video This will play a video - Image of doctors during operation

TOGETHER, WE ACHIEVED PATIENT INSPIRED INNOVATION AHEAD OF TIME

The Future is Here

At Medtronic, we understand that innovation is not driven by ourselves alone. We believe in working with you to apply the full power of technology for better patient outcomes. We do this by collaborating on meaningful innovation with you to create the most advanced and disruptive technologies and best-in-class therapies for your patients.

PRODUCT INNOVATION

Click on the images below to learn more about our best in class products. 

TOGETHER, WE ACHIEVED GROUND BREAKING INNOVATION AHEAD OF TIME

MEDTRONIC INNOVATION

SMARTER DEVICES BETTER PATIENT CARE

MIT Technology Review Insights examines how smart medical technology is revolutionizing medicine and the future of personalized patient care.

VIEW PAPER (opens new window)
VR doctor

PARTNER IN CARE

Your partner in
 Advancing digital
patient care, Everyday.

Innovation doesn’t end at implant.

LEARN MORE (opens new window)
Doctor and Patient exchanging information digitally

ACADEMY

MEDTRONIC ACADEMY LEARNING PLANS: COMPREHENSIVE
DEVICE FOLLOW-UP
EDUCATION

  

Learn More(opens new window)

References

1

Using Modeling Study of 20 different patient anatomies, selected to include patients with atria ranging from 38-197 mL RA volumes. Across tested anatomies, the C304-HIS improved fixation success rate vs C315HIS in larger RAs with volumes between 110 mL and 139 mL (vs. C315).

2

Gierula J, Paton MF, Witte KK. Advances in cardiac resynchronization and implantable cardioverter/defibrillator therapy: Medtronic Cobalt and Crome. Future Cardiol. 2021 Jul;17(4):609-618.

3

Ousdigian KT, Rosemas S, Koehler JL, Cheng YJ, Kloosterman EM. New Algorithms and Tailored Programming of Insertable Cardiac Monitors Reduce Alerts and Time Required to Follow Patients. Circulation 142(Suppl 3): 16568.

4

Van Heel L, et al. Circulation. 2019;140:A11830

5

2020 MedTech Breakthrough Award Winners - Best Overall Connected Healthcare Solution: Medtronic, MyCareLink™ Heart mobile app: https://hitconsultant.net/2020/05/21/2020-medtech-breakthrough-award-winners/#.YJ1jD6gzZPY

6

Seiler A, et al. Clinic time required for remote and in-person management of cardiac device patients: Time and motion workflow evaluation. JMIR Cardio (Forthcoming). doi:10.2196/27720

7

Steinwender C, Khelae SK, Garweg C, et al. Atrioventricular synchronous pacing using a leadless ventricular pacemaker: Results from the MARVEL 2 study. JACC Clin Electrophysiol. Published online November 2, 2019.

8

Massdevice, Medtronic lands CE Mark for Micra AV transcatheter pacing system, June 15, 2020, https://www.massdevice.com/medtronic-micra-av-lands-ce-mark/

9

Auricchio A, et al. Heart Rhythm. 2015;12:926-936.

10

Swenson DJ, et al. A Direct Comparison of a Novel Antitachycardia Pacing Algorithm Against Present Methods Using Virtual Patient Modeling, Heart Rhythm (2020)

BRIEF STATEMENT

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan™ device, see the MRI SureScan™ technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.(opens new window)

For applicable products, consult instructions for use on www.medtronic.com/manuals(opens new window). Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

Important Reminder: This information is intended only for users in markets where Medtronic products and therapies are approved or available for use as indicated within the respective product manuals. Content on specific Medtronic products and therapies is not intended for users in markets that do not have authorization for use.